Ongoing research aims to improve the efficacy and safety of PD-L1 inhibitors. Combination therapies, which use PD-L1 inhibitors alongside other treatments like chemotherapy, radiation, or other immunotherapies, are being actively investigated. Additionally, new biomarkers are being explored to better predict patient response and tailor treatments more effectively.
